Anti-vascular endothelial growth factor therapy in diabetic macular edema: real-life outcomes from a multicenter study in Turkey over 36 months

• DOI: 10.1007/s10792-022-02375-6
• Publication Date: 2022-07-13T07:03:46Z
• Authors: Ali Hakan Durukan; Nurten Unlu; Mehmet Onen; Mehmet Numan Alp; Yağmur Seda Yeşiltaş; Defne Kalayci; Mehmet Akif Acar; Mehmet Ali Sekeroglu; Mehmet Citirik; Ayse Gul Kocak Al...; Dicle Hazirolan; Murat Kucukevcili...; Pinar Cakar Ozdal; Yasin Toklu; Tolga Bicer; Nagihan Ugurlu; Ozlem Budakoglu; Zeliha Yazar; Nil Irem Ucgun; Kurtulus Serdar; Sibel Doguizi; Yasemin Ozdamar Erol; Cemile Ucgul Atilgan; Mucella Arikan Yo...; Dilek Ozcelik Soba; Nilufer Berker; Ceyda Baskan; Esra Safak Yilmaz
• Keywords: Vascular Endothelial Growth Factor A; Diabetic Retinopathy; Turkey; Angiogenesis Inhibitors; Macular Edema; 3. Good health; Bevacizumab; 03 medical and health sciences; 0302 clinical medicine; Ranibizumab; Intravitreal Injections; Diabetes Mellitus; Humans; Retrospective Studies

Abstract Purpose: This study aimed to report the visual and anatomical outcomes of intravitreal anti-VEGF treatment for diabetic macular edema (DME) in a real-world clinical setting from Turkey over 36 months.Methods: This is a retrospective, multicenter (7 cites) study. The medical records of 1072 eyes (both previously treated and naive eyes) of 706 consecutive patients with visual impairment due to center-involving DME treated with intravitreal anti-VEGF injections between April 2007 and February 2017, were reviewed. The eyes were divided into mutually exclusive three groups based on the duration of follow-up (12, 24, or 36 months). Primary outcome measures were changes in visual acuity (VA) and central macular thickness (CMT) from baseline to final visit in each cohort, frequency of visits, and intravitreal anti-VEGF injections. As secondary endpoints, VA outcomes were assessed in subgroups stratified by baseline VA [<70 ETDRS letters and ≥ 70 ETDRS letters] and loading dose status of anti-VEGF injections.Results: VA increased by a mean of 8.2 letters (12-month cohort, p<0.001), 5.3 letters (24-month cohort, p<0.001), and 4.4 letters (36-month cohort, p=0.017) at final visits. The eyes with <70 VA letters achieved more significant VA improvement at final visits in all cohorts compared with eyes with >70 VA letters (p<0.001). The mean decreases in CMT from baseline to last visits at 12-, 24-, and 36- month cohorts were -100.5, -107.7, and -114.3 µm, respectively (p<0.001). The mean number of injections given were 4.6, 2.3, and 1.8 during years 1 to 3, respectively. Patients who received loading dose showed greater VA gains than those who did not in all follow-up cohorts.Conclusion: Our study revealed that anti-VEGF treatment improved VA and CMT over a follow-up of 36 months. Although these real-life VA outcomes following anti-VEGF therapy for DME were similar to other real-life studies, they were inferior to those noted in randomized controlled trials, mainly due to undertreatment.